Bal Pharma Standalone September 2021 Net Sales at Rs 67.00 crore, up 4.24% Y-o-Y
NULL12-11-2021
BAL PHARMA LTD. - 524824 - Unaudited Standalone & Consolidated Financial Results 30.09.2021
The Board of Directors of the Company has met to day and inter alia transacted the following business. 1.Taken on record and approved the Unaudited financial results of the Company for the quarter and half year ended 30.09.2021. Copy of the standalone and consolidated financial results along with the limited review reports issued by the statutory auditors of the Company is enclosed, for submission to the exchanges. The meeting commenced at 16.30 p.m and concluded at 18.00 on 11.11.2021.11-11-2021
BAL PHARMA LTD. - 524824 - Board Meeting Outcome for Outcome Of The Board Meeting
The Board of Directors of the Company has met to day and inter alia transacted the following business. 1.Taken on record and approved the Unaudited financial results of the Company for the quarter and half year ended 30.09.2021. Copy of the standalone and consolidated financial results along with the limited review reports issued by the statutory auditors of the Company is enclosed, for submission to the exchanges. The meeting commenced at 16.30 p.m and concluded at 18.00 on 11.11.2021.11-11-2021
BAL PHARMA LTD. - 524824 - Board Meeting Intimation for Approval Of Unaudited Financial Results For The Quarter And Half Year Ended 30.09.2021.
BAL PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/11/2021 ,inter alia, to consider and approve Unaudited financial results ( Standalone and Consolidated ) of the Company for the quarter and half year ended 30.09.2021.22-10-2021
BAL PHARMA LTD. - 524824 - Shareholding for the Period Ended September 30, 2021
Bal Pharma Ltd has submitted to BSE the Shareholding Pattern for the Period Ended September 30, 2021. For more details, kindly Click here13-10-2021
BAL PHARMA LTD. - 524824 - Compliance Certificate As Per Regulation 7(3) Of SEBI (LODR) Regulations.
We are submitting to the exchange confirmation as prescribed under the above mentioned regulation, for the half year ended 30.09.2021.08-10-2021
BAL PHARMA LTD. - 524824 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
We wish to inform the exchanges that the Company had met the following Institutional investors/Analysts on 7th October 2021, through audio visual means. Sl No Analyst/Investor's Name 1 Maitri Financial Services 2 PCS Securities Ltd Bal Pharma Ltd was represented by Mr.Shailesh Siroya , Managing Director.08-10-2021
BAL PHARMA LTD. - 524824 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Based on the certificate's received from our R&T; agents i.e TSR Darashaw Ltd, we would like to confirm that the details of securities dematerialized / rematerialized during the quarter ended on 30.09.2021 have been furnished to all the stock exchanges where the equity shares of the Company are listed, within the prescribed time limit. The Share certificates received for dematerialization, if any has been mutilated and cancelled after due verification and the name of the depository has been substituted in the records as registered owner, within 15 days of the receipt of the certificate of security.04-10-2021
BAL PHARMA LTD. - 524824 - Statement Of Investor Complaints For The Quarter Ended September 2021
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0000 Name of the Signatory :- VENUMADHAVA REDDYDesignation :- Any Other01-10-2021
BAL PHARMA LTD. - 524824 - Closure of Trading Window
Pursuant to the Code of conduct of the Company and as per the amended provisions of SEBI (Prohibition of Insider Trading) Regulations, 2015, we wish to inform the exchange that the trading window for dealing with the securities of the Company on the designated employees and their relatives will be closed from 1st October 2021 and up to 48 hours of the declaration of the financial results of the Company, for the quarter & half year ended 30/09/2021. The date of the Board meeting for declaration of the financial results for quarter and half year ended 30th September 2021 will be intimated to the exchange in due course.30-09-2021